DWTX – dogwood therapeutics, inc. (US:NASDAQ)
Stock Stats
News
DWTX: Financing Secures Funding Through Phase 2b Data Readout [Yahoo! Finance]
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 [Yahoo! Finance]
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
Dogwood Therapeutics (NASDAQ:DWTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Form EFFECT Dogwood Therapeutics,
Form PRE 14A Dogwood Therapeutics, For: Mar 11
Form 8-K Dogwood Therapeutics, For: Jan 20
Form S-3 Dogwood Therapeutics,
Form 8-K Dogwood Therapeutics, For: Jan 09
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.